Although it rejected Alimentation Couche-Tard’s enhanced offer of approximately $5.91 billion (CA$7.8 billion), Caltex nevertheless believes that the convenience store and service station operator is a “serious” and “trustworthy” contender.
For this reason, the Australian company decided to offer the Quebec multinational the opportunity to have access to nonpublic information so that it could make a higher bid.
Many other publications overlook breaking business headlines focused on investing. Born2Invest mobile app helps readers stay on top of the latest news and financial affairs of the world.
“We received feedback from shareholders and thought it was important to take a constructive approach,” explained Caltex Chief Financial Officer Matthew Halliday on Thursday, December 5, at a conference for investors and analysts.
However, the company has not received a response from Couche-Tard since the announcement of the offer rejection. If the transaction were to proceed, it would become the largest acquisition of the Quebec giant.
On Tuesday, December 3, Couche-Tard had indicated by email that they had “nothing to add on the subject at this time.” At midday on Thursday, December 5, the company did not answer the questions sent by The Canadian Press.
The Quebec giant, which wants to double its size within five years, made an initial offer of $21.89 (A$32) for each Caltex share last October, but it was rejected because its price was deemed inadequate. The latter had come back to the table by proposing $23.60 (A$34.50) for each share of Caltex, which operates a network of some 2000 service stations, in addition to owning a refinery and fuel distribution and transportation assets.
Caltex management briefly commented on Couche-Tard’s offensive, noting that profits are expected to decline this year, in addition to announcing the sale of 25 sites that sell fuel. It also had to defend its decision to allow the Laval company to have access to inside information – in exchange for a confidentiality agreement – when there is no firm offer on the table.
“It’s not to do a pre-check,” said Mr. Halliday. It’s more to offer a way to come back with a proposal that could generate more value for our shareholders.” At a price of $23.60 (A$34.50) per share, Couche-Tard’s proposal represents a premium of approximately 16% over the closing price of Caltex’s stock on November 25, prior to the announcement of the receipt of an offer to purchase.
Caltex has nearly 6630 employees. On the Sydney Stock Exchange on Thursday, December 5, it was trading on stock at $23.52 (A$34.38), slightly below the $23.60 (A$34.50) price proposed by Couche-Tard in its enhanced proposal.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in leDetroit, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
BB Biotech: Positive development in a volatile market environment
The total shareholder return in 2020 was 19.3% in CHF and 18.1% in EUR, slightly below the performance of the...
Bitcoin slips back to $53,000 and major altcoins go lower on February 22nd
The fall seen in the price of Bitcoin on February 22 was also strongly felt among exponents such as Ethereum...
The keys to ESG investment in 2021 in the face of growing interest and profitability
While all the data point to the fact that investment under climate, social and corporate governance criteria is increasingly in...
New investments in the Fez-Meknes Region
As part of the industrial revival strategy, the Fez-Meknes Region should welcome 95 potential projects identified in the project bank....
Rebound in pharma and healthcare operations: 14% increase in 2020
The volume of mergers and acquisitions in the pharmaceutical and healthcare sector increased by 25% compared to the first half...
Cannabis6 days ago
The ANMAT will allow the importation of cannabis-based products in Argentina
Featured7 days ago
Banca Progetto prepares to launch instant lending for consumer credit
Featured7 days ago
Repsol hires Linklaters and Uría to list its renewable energy subsidiary
Crypto6 days ago
How LODEpay’s Price Oracle is Tackling Silver Spot Price Manipulation